Dusseldorf - Delayed Quote EUR

Roche Holding AG (RHO5.DU)

281.60

-0.80

(-0.28%)

As of 9:30:14 AM GMT+2. Market Open.

Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer

Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy121% reduction in the risk of death was seen in the pre-specified subgroup of people with lymph node-positive disease1Data to be presented as a late-breaking abstract at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Congress Basel, 13 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast I

GlobeNewswire 3 hours ago

RHHBF

RHHBY

RHHVF
Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer

SOUTH SAN FRANCISCO, Calif., May 13, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, announced today statistically significant final overall survival (OS) results from the Phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. After ten years, the risk of death was reduced by 17% f

Business Wire 3 hours ago

RHHBF

RHHBY

RHHVF
Roche plans $700m manufacturing plant in the US

The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.

Pharmaceutical Technology 15 hours ago

ROG.SW
Roche plans $550M expansion of Indianapolis site to manufacture CGMs

Roche Diagnostics plans to produce glucose monitors at the site within three years and prepare for future generations of its sensors.

MedTech Dive 17 hours ago

ROG.SW
Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it plans to invest up to $550 million in its Diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems – marking a new milestone in Roche's long history of revolutionizing healthcare across the globe.

PR Newswire 18 hours ago

RHHBF

RHHBY

RHHVF
Roche boosts US presence with new $700 million North Carolina facility

The new facility, based in Holly Springs, North Carolina, will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines. Separately, Roche also announced plans to invest up to $550 million in its diagnostics site in Indianapolis by 2030, to manufacture continuous glucose monitoring systems.

Reuters 19 hours ago

ROG.SW
Roche and Genentech Announce New North Carolina Manufacturing Facility

SOUTH SAN FRANCISCO, Calif., May 12, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today plans to invest more than $700 million in a new 700,000 square foot state-of-the-art drug manufacturing facility in Holly Springs, NC.

Business Wire 20 hours ago

RHHBF

RHHBY

RHHVF
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.

The Wall Street Journal 23 hours ago

069620.KS

CHGCF

CHGCY
Trump is hailing $2 trillion in new company investments. Most of it comes from Big Tech.

President Trump has touted $2 trillion in new company investments since Inauguration Day. The lion's share comes from Big Tech, according to a Yahoo Finance analysis.

Yahoo Finance 2 days ago

ORCL

RHHBF

RHHBY
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025

PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.

Zacks 3 days ago

PRTA

ROG.SW
Zealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...

Zealand Pharma AS (ZLDPF) reports robust financials and transformative partnerships, setting the stage for future growth in the obesity and rare disease markets.

GuruFocus.com 4 days ago

ZEAL.CO

ROG.SW
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.

Zacks 5 days ago

SRPT

ARWR

ROG.SW
Roche introduces diagnostic test for liver fibrosis severity assessment

The test operates on Roche's cobas analysers and requires one assay, delivering outcomes in 18 minutes.

Medical Device Network 5 days ago

ROG.SW
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide1The test delivers results in just 18 minutes on Roche’s cobas analysers, providing a fast and reliable diagnostic method.The test enables earlier identification of patients with significant liver fibrosis, potentially improving outcomes through timely management and access to emerging therapies. Basel, 0

GlobeNewswire 7 days ago

RHHBF

RHHBY

RHHVF
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Eli Lilly CEO says Trump tariff threat has already achieved the goal of repatriating manufacturing in pharma.

Yahoo Finance 11 days ago

PFE

JNJ

RHHBF
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example at home1-4 Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings3Phesgo has the potential to reduce treatment administration costs by up to 80% in Western Europe, and 85% of patients prefer SC over IV administ

GlobeNewswire 13 days ago

RHHBF

RHHBY

RHHVF
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer

The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level of diagnostic precision not possible with traditional manual scoring methods. This Breakthrough Device Designation (BDD) demonstrates Roche’s continued innovation in companion diagnostics and digital pathology to enable more precise diagnosis in oncology. Basel, 29 Apri

GlobeNewswire 14 days ago

RHHBF

RHHBY

RHHVF
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

SOUTH SAN FRANCISCO, Calif., April 25, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil). The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%. For the key secondary endpo

Business Wire 18 days ago

RHHBF

RHHBY

RHHVF
Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push

Roche posted higher-than-expected first-quarter sales, driven by robust demand for its key drugs, as the company takes active steps to preempt looming U.S. import tariffs.

The Wall Street Journal 19 days ago

RHHBF

RHHBY

RHHVF
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

Group sales grew by 6%1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions.Pharmaceuticals Division sales rose by 8% (9% in CHF) on continued strong demand for a broad range of our medicines; top growth drivers were Phesgo (breast cancer), Vabysmo (severe eye diseases), Xolair (allergies) and Hemlibra (haemophilia A).Diagnostics Division sales remained stable with high demand across products and regions offsetting the impact of the rec

GlobeNewswire 19 days ago

RHHBF

RHHBY

RHHVF

Performance Overview

Return	RHO5.DU	MSCI WORLD (^990100-USD-STRD)
YTD	+19.25%	+2.14%
1-Year	+19.25%	--
3-Year	+29.08%	+43.89%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Roche Holding AG (RHO5.DU)

Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer

Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer

Roche plans $700m manufacturing plant in the US

Roche plans $550M expansion of Indianapolis site to manufacture CGMs

Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub

Roche boosts US presence with new $700 million North Carolina facility

Roche and Genentech Announce New North Carolina Manufacturing Facility

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

Trump is hailing $2 trillion in new company investments. Most of it comes from Big Tech.

Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025

Zealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

Roche introduces diagnostic test for liver fibrosis severity assessment

Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer

New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

Performance Overview